Previous close | 16.35 |
Open | 16.25 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 16.35 - 16.35 |
52-week range | 16.06 - 22.85 |
Volume | |
Avg. volume | 741 |
Market cap | 8.851B |
Beta (5Y monthly) | 0.21 |
PE ratio (TTM) | 22.40 |
EPS (TTM) | 0.73 |
Earnings date | N/A |
Forward dividend & yield | 0.41 (2.50%) |
Ex-dividend date | 28 Dec 2023 |
1y target est | N/A |
Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that post-hoc analysis data from the Phase 2b study of rocatinlimab (AMG 451/KHK4083), an investigational product in patients with moderate-to-severe atopic dermatitis (AD), will be presented at the upcoming European Academy of Dermatology and Venereology (EADV) Congress 2023 in Berlin, Germany in October 11-14, 2023.
Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a top 50 global specialty pharmaceutical company, today assumes primary commercial leadership for PrCRYSVITA™ (burosumab injection) in the United States and Canada from Ultragenyx Pharmaceutical, Inc., a transition planned for from the start of their decade-long collaboration. Initially discovered and developed by Kyowa Kirin, CRYSVITA is used for the treatment of X-linked hypophosphataemia (XLH) in adult and pedi
SAN DIEGO & TOKYO, December 05, 2022--MEI Pharma, Inc. (Nasdaq: MEIP), a pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a Japan-based global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced that after receiving the most recent guidance from a late November meeting with the U.S. Food and Drug Administration (FDA), the companies are discontinuing glob